Inspection Record

Avir Pharma Inc. — Health Canada Inspection Findings

Health CanadaInspected 2022-09-13 3 findingsLaboratory and QC controlsStability and storage

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

The written protocol and/or the assessment of the test method transfer was inadequate.

2Stability and storage

The ongoing stability program for a drug was inadequate.

3Stability and storage

The evidence used to demonstrate the transportation and/or storage conditions of each lot or batch of the drug was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2022-09-13. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Avir Pharma Inc. company profile — full history Health Canada documents, 2022 Go to Findings search